Congenital Amegakaryocytic Thrombocytopenia (CAMT) Cell Models for Research

Congenital amegakaryocytic thrombocytopenia (CAMT) is an extremely rare inherited bone marrow failure syndrome, with an estimated incidence of 1 in 1,000,000 live births. It is characterized by severe thrombocytopenia and absence of megakaryocytes in the bone marrow, leading to early onset of bleeding symptoms. Without treatment, CAMT progresses to pancytopenia and bone marrow failure, with a 5-year survival of less than 50% if untreated. Hematopoietic stem cell transplantation (HSCT) is the only curative therapy, but it carries significant morbidity and mortality. The disease is caused by mutations in the MPL gene, which encodes the thrombopoietin receptor, leading to impaired megakaryopoiesis and hematopoietic stem cell maintenance.

CAMT serves as an ideal model for studying megakaryopoiesis, thrombopoietin signaling, and hematopoietic stem cell biology. The disease is monogenic, with a clear genotype-phenotype correlation, making it amenable to functional studies. Public datasets, such as those from the International Bone Marrow Failure Syndrome Registry, provide clinical and genetic data for research. Open questions include the molecular mechanisms of disease progression, the role of residual MPL activity, and the development of targeted therapies. Gene-edited cell models, such as MPL knockout or knock-in lines, are essential tools for these investigations.

The primary pathway affected in CAMT is the thrombopoietin (THPO) / MPL signaling pathway. The steps are as follows:

1. THPO binds to the MPL receptor on hematopoietic stem cells and megakaryocyte progenitors.

2. This binding induces receptor dimerization and activation of JAK2.

3. JAK2 phosphorylates MPL and downstream signaling molecules, including STAT3, STAT5, and MAPK.

4. These signals promote cell survival, proliferation, and differentiation into megakaryocytes.

5. In CAMT, loss-of-function mutations in MPL disrupt this signaling, leading to failure of megakaryopoiesis and hematopoietic stem cell exhaustion.

Additionally, impaired MPL signaling affects the maintenance of hematopoietic stem cells, contributing to bone marrow failure.

Data from ClinVar and COSMIC databases.

The THPO/MPL pathway is central, but other networks are also affected:

• • JAK/STAT pathway: Key nodes include JAK2, STAT3, STAT5. Impaired activation leads to reduced expression of target genes involved in cell cycle and differentiation.
• • MAPK/ERK pathway: Involves RAS, RAF, MEK, ERK. Disruption affects proliferation and differentiation.
• • PI3K/AKT pathway: Involves PI3K, AKT, mTOR. Impaired signaling affects survival and metabolism.
• • Other pathways: Notch, Wnt, and Hedgehog pathways may also be deregulated, affecting hematopoietic stem cell self-renewal.

Organoids derived from patient iPSCs are emerging as more physiologically relevant models, allowing the study of megakaryopoiesis in a three-dimensional context.

• • PDX models: Patient-derived xenografts in immunodeficient mice, used to study CAMT pathophysiology and test therapies.
• • GEMMs: Genetically engineered mouse models with Mpl knockout (Mpl-/-) recapitulate CAMT phenotypes, including thrombocytopenia and bone marrow failure.
• • Induced models: Conditional knockout mice using Cre-lox systems allow temporal and tissue-specific deletion of Mpl.
• • Zebrafish models: Mpl knockdown or knockout in zebrafish to study early hematopoiesis.

CRISPR-based gene editing enables the generation of isogenic cell lines with precise mutations in MPL or other genes. For example:

• • MPL knockout cell lines: Complete loss of MPL function, mimicking severe CAMT.
• • MPL point mutation knock-in lines: Introduction of specific missense mutations found in patients, allowing study of partial loss of function.
• • THPO knockout cell lines: To study the ligand-receptor interaction.

These models are sequence-verified and commercially available, accelerating research by providing consistent and reproducible systems. They are essential for functional validation, drug screening, and mechanistic studies.

Gene-edited cell lines allow the validation of candidate genes identified in genomic studies. For example, knocking out MPL in a megakaryocytic cell line can confirm its role in thrombopoietin signaling and megakaryocyte differentiation. Similarly, introducing patient-specific mutations into a wild-type background can demonstrate causality. These models are also used in CRISPR screens to identify modifiers of MPL signaling or synthetic lethal partners.

Isogenic pairs (wild-type vs. MPL knockout) are used to screen for compounds that can bypass MPL signaling and promote megakaryopoiesis. They are also used to test drugs that target downstream pathways, such as JAK2 inhibitors. Resistance mechanisms can be studied by exposing cells to drugs and selecting for resistant clones, then identifying genetic changes.

CRISPR-based synthetic lethality screens can identify genes that are essential in MPL-deficient cells but not in wild-type cells, providing potential therapeutic targets. Gene-edited cells can also be used to identify biomarkers of disease progression or response to therapy by analyzing gene expression and protein profiles.